Mirum Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue: | |||
| Product sales, net | $521,312 | $336,409 | $178,874 |
| License and other revenue | — | 479 | 7,500 |
| Total revenue | 521,312 | 336,888 | 186,374 |
| Operating expenses: | |||
| Cost of sales | 100,240 | 81,643 | 47,039 |
| Research and development | 186,178 | 140,630 | 102,609 |
| Selling, general and administrative | 257,030 | 202,221 | 145,880 |
| Total operating expenses | 543,448 | 424,494 | 295,528 |
| Loss from operations | (22,136) | (87,606) | (109,154) |
| Other income (expense): | |||
| Interest income | 12,727 | 13,792 | 13,735 |
| Interest expense | (14,389) | (14,311) | (15,105) |
| Loss from termination of revenue interest purchase agreement | — | — | (49,076) |
| Other income (expense), net | 2,371 | 1,213 | (2,824) |
| Loss before provision for income taxes | (21,427) | (86,912) | (162,424) |
| Provision for income taxes | 1,936 | 1,030 | 991 |
| Net loss | $(23,363) | $(87,942) | $(163,415) |
| Net loss per share, basic and diluted | $(0.47) | $(1.85) | $(4.00) |
| Weighted-average shares of common stock, basic and diluted | 50,198,304 | 47,522,594 | 40,885,124 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.